tbuckley/cabot-search huggingface dataset:
Abstract 1241: Targeting the IL-13 receptor alpha 2 with novel antibody-drug conjugates for the treatment of cancer.
Authors: Dangshe Ma, Haige Zhang, Fang Jin, Manoj Charati, Kiran Khandke, Judy Lucas, Max Follettie, L. Nathan Tumey, Hans-Peter Gerber, Lioudmila Tchistiakova, Puja Sapra
Journal: Cancer Research (2013)

Abstract The IL-13 receptor alpha 2 (IL-13Rα2) is a transmembrane protein that is highly expressed on several cancers including glioblastoma, ovarian, pancreatic cancers. It can internalize after binding to its ligand IL-13 or in response to ligation with an antibody. In addition, we have discovered that IL-13Rα2 is up-regulated in tumor cell lines that are resistant to chemotherapeutic drugs. These properties make IL-13Rα2 an attractive target for antibody-drug conjugate (ADC), an emerging modality of molecularly targeted cancer therapies. A humanized monoclonal antibody, hAB08 with an affinity of 0.17 nM to the soluble recombined hIL-13Rα2, was conjugated with two novel microtubule inhibitors (MTIs), MTI1 and MTI2, developed by Pfizer. In vitro cytotoxicity of the conjugates was tested against IL-13Rα2 positive and negative cell lines. These conjugates were effective against the IL-13Rα2 positive cell lines (PC3MM2 and A375), having an IC50 ranging from 1.1 to 3.8 ng Ab/mL. However, both of the ADCs were not active against the IL-13Rα2 negative H460 cell line. When treating mice with established human PC3MM2 and A375 tumors, these conjugates were efficacious at 3 mg/kg in reducing tumor growth. In the PC3MM2 model, treatment with hAB08-MTI1 and hAB08-MTI2 resulted in 5 out of 8 or 3 out of 8 animals without measurable tumors at Day 76, respectively. In contrast, the vehicle control group and control ADC (hIgG8.8-MTI1 and hIgG8.8-MTI2) groups were terminated at Day 15, 15, 19 due to the large size of tumors, respectively. These in vitro and in vivo results demonstrate potent antitumor activities of hAB08-MTI1 and hAB08-MTI2 against IL-13Rα2 positive tumors. The findings support the development of novel hAB08-MTI1 or hAB08-MTI2 ADCs as a molecularly targeted therapy for cancer patients that are resistant to standard chemotherapy. Citation Format: Dangshe Ma, Haige Zhang, Fang Jin, Manoj Charati, Kiran Khandke, Judy Lucas, Max Follettie, L. Nathan Tumey, Hans-Peter Gerber, Lioudmila Tchistiakova, Puja Sapra. Targeting the IL-13 receptor alpha 2 with novel antibody-drug conjugates for the treatment of cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1241. doi:10.1158/1538-7445.AM2013-1241
Quitting Smoking: Nicotine vs Placebo Gum
Authors: Terry A. Jacobson
Journal: JAMA (1989)

<h3>To the Editor.—</h3> Hughes et al<sup>1</sup>add another well-designed randomized study to the literature on smoking cessation. However, the authors' conclusions about the ineffectiveness of nicotine gum with brief physician counseling need further discussion. First, their sample size had inadequate power to detect a 10% difference in quit rates. They attempt to justify their sample size by commenting that a lower quit rate would not be "clinically significant," given that physician advice alone results in a 5% quit rate. This statement coupled with the results of their survey—that the majority of primary care physicians would not use a medicine if it would only result in a 5% increase in quit rates—highlight the crux of the problem with smoking cessation. One of the major reasons physicians do not counsel smokers, either with or without nicotine gum, is that it is their perception that quit rates of 5% to 10% are
710-3 Stent Placement is Safe and Effective in the Treatment of Older (&amp;gt;4 Years) Saphenous Vein Graft Lesions
Authors: S. Chiu Wong, Ya Chien Chuang, Mun K. Hong, Augusto D. Pichard, Lowell F. Saller, Kenneth M. Kent, Kathi Donovan, Donald S. Baim, Richard A. Schatz, Martin B. Leon
Journal: Journal of the American College of Cardiology (1995)
Consent for Invasive Procedures in the Newly Deceased-Reply
Authors: Robert McNamara
Journal: JAMA (1995)

<h3>In Reply.</h3> —Drs Brattebø and Wisborg raise an interesting point about practicing procedures on living patients. However, consent forms for surgery and other procedures are usually worded in such a way that the attending physicians "may utilize assistants" as they see fit. In my practice, this is how many such teaching activities are justified on living patients. I do agree that in circumstances such as the resuscitation of a dying patient, this is a gray area, and the patient and family are often unaware of what actually transpires. On the other hand, I do not think that having a narrow majority of patient families in the studies<sup>1</sup>agree to such teaching activities creates a clear mandate to allow for presumed consent for endotracheal intubation. Ideally, a policy should be crafted that all levels of the health care team would be aware of and support. Input into such a policy
Retroviral Transduction and Engraftment Ability of Primate Hematopoietic Progenitor and Stem Cells Transduced Under Serum-Free versus Serum-Containing Conditions
Authors: Kimberley A. Kluge, Aylin C. Bonifacino, Stephanie Sellers, Brian A. Agricola, Robert E. Donahue, Cynthia E. Dunbar
Journal: Molecular Therapy (2002)

The ability to efficiently transduce hematopoietic stem and progenitor cells under serum-free conditions would be desirable for safety and standardization of clinical gene therapy protocols. Using rhesus macaques, we studied the transduction efficiency and engraftment ability of CD34-enriched SCF/G-CSF mobilized progenitor cells (PBSC) transduced with standard amphotropic marking vectors under serum-free and serum-containing conditions. Supernatants were collected from producer cells 16 hours after serum-free medium or medium containing 10% fetal calf serum was added. Vector titers were approximately two- to threefold higher when producer cells were cultured in serum-containing medium. However, retroviral transduction of rhesus CFU-GM was improved using serum-free vector-containing medium. For analysis of engraftment with transduced cells, three macaques had CD34+ peripheral blood stem cells split into two fractions for transduction. One fraction was transduced using serum-free vector-containing medium, and the other fraction was transduced using standard serum-containing medium. The two fractions were re-infused simultaneously following total body irradiation. In all three animals, there was equivalent marking from both vectors for 7-9 months post-transplantation. These data are encouraging regarding the removal of serum-containing medium from clinical hematopoietic cell transduction protocols, given the lack of a detrimental effect on transduction and engraftment with transduced cells.
A Cardiac Silhouette Seen on Chest X-Ray
Authors: Phillip J. Cozzi
Journal: Annals of Internal Medicine (1990)

Ad Libitum15 September 1990A Cardiac Silhouette Seen on Chest X-RayPhillip J. Cozzi, MDPhillip J. Cozzi, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-6-486_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWampum bag or buffalo head,A half-deflated basketball,A fist, a gourd, a sack of seedOut all night in the rain.A triangle with corners trimmed,The sack a Santa carries,A boy with both knees pulledTight up under his chin.A plum, a pear or mango fruit,An amber drop, misshapen,A saddle purse or betel nut,Walnut in its shell.A chocolate-covered cherry treat,The partly open cotton boll,Gum drop, teardrop, apricot,Grapes that hang in bunches.A drawstring purse, fig or face,The outline of a fishhook,The summer haystacks by Monet,Embryo, ellipse.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: 9219 Shields Brookfield, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 September 1990Volume 113, Issue 6Page: 486-486KeywordsEmbryosKneesThorax ePublished: 1 December 2008 Issue Published: 15 September 1990 Copyright & Permissions© 1990 American College of PhysiciansPDF downloadLoading ...
Improvement of Allergic Rhinitis Symptoms in Children Receiving Hymenoptera Immunotherapy
Authors: Savitree Padungpak, Wiparat Manuyakorn, Wasu Kamchaisatian, Suwat Benjaponpitak, Soamarat Vilaiyuk, Cherapat Sasisakulporn, Wanlapa Teawsomboonkit
Journal: Journal of Allergy and Clinical Immunology (2013)
Dynamic Cardiac Auscultation and Phonocardiography
Authors: Aldo A. Luisada
Journal: JAMA (1979)

This ponderous tome (3 kg) suffers from the beginning because of a clash with its title. This is an atlas, and while auscultation is not discussed, apex cardiography and carotid pulse tracings are included. Several general shortcomings are obvious: (1) The tracings are taken with old equipment, probably of the 1950 vintage. (2) They are all taken with a similar filtration, ie, high-pass filters with slow slope, resulting in a combination of low- and high-frequency vibrations, which is neither scientifically useful nor similar to the response of the human ear. (3) The area of recording is labeled only seldom, while the characteristics of the filters are never mentioned. Such indications had been agreed on and considered essential by international committees from 1950 to 1965. (4) There is a plethora of abbreviations (102). (5) The information supplied in the legends is inadequate for an undergraduate student and fails to give a
The Tobacco Habit.
Authors: Edward J. Brown
Journal: JAMA (1899)

Minneapolis, Minn., May 9, 1899. <h3>To the Editor:</h3> —Will you permit me to voice a word of commendation for the able, possibly somewhat extreme, but in the main, just, statement of the facts connected with the use of tobacco, contained in Dr. Woods' article in theJournalof April 1. Dr. Woods is entitled to the thanks of every clean-minded and clean-bodied man and woman for such an arraignment of the profession for throwing its influence in the direction of such debasing forces. I can not believe that many men, even among users of tobacco, would say "amen" to Dr. McKenna's attempted reply in theJournalof April 22. I have known a great many users of tobacco, but I have known very few of them who were willing either to commend the habit or to recommend it to their sons and daughters. If tobacco is as desirable as Dr.
Accuracy of Clinical Blood Gas Measurements
Authors: John W. Brantigan
Journal: JAMA (1974)

To the Editor.—  In the development of catheters for continuous measurement of blood gases by mass spectrometry ( J Appl Physiol 28:375-377, 1970; 32:276-282, 1972), it has been necessary to compare data with results of analyses by ordinary instruments that do not provide an absolute standard. In order to assess the accuracy of clinical blood gas measurements, a study was done in dogs in which split samples of arterial blood were analyzed on four separate instruments of three independent institutions.  A dog weighing 20 kg (44 lb) was anesthetized with pentobarbital sodium (25 mg/kg) and placed on a respirator. Thefemoral artery was cannulated percutaneously and a Teflon catheter inserted for continuous measurement of blood gases by mass spectrometry. A Y-piece allowed withdrawal of arterial blood samples through the same puncture site. When the spectrometer indicated stable blood gas levels, split samples of arterial blood were obtained in heparinized glass syringes
Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization.
Authors: MA Vollebergh, PM Nederlof, LF Wessels, MK Schmidt, SA Joosse, E van Beers, F Froklage, M Holtkamp, JG Schrama, J Wesseling, M Hauptmann, M de Bruin, S Rodenhuis, SC Linn
Journal: Cancer Research (2009)

Abstract Abstract #6050 Background: Breast cancer cells lacking the DNA repair mechanism Homologous Recombination (HR) have recently been shown to be hypersensitive to bifunctional alkylating agents such as carboplatin and poly(ADP-ribose)polymerase(PARP)-inhibitors, a novel class of targeted agents. We have previously reported the construction of an array Comparative Genomic Hybridization (aCGH) classifier that detects the characteristic copy number aberrations of BRCA1-mutated tumors which are thought to be caused by HR deficiency. We hypothesized that metastatic breast cancer patients with tumors harboring such a BRCA1-profile may specifically benefit (longer progression-free survival (PFS)) from intensive treatment with bifunctional alkylating agents compared to patients without this tumor-profile.&amp;#x2028; Methods: We isolated DNA from formalin-fixed paraffin-embedded primary tumor tissue collected from 3 prior studies carried out in our institute, in which metastatic breast cancer patients received intensive alkylating chemotherapy with carboplatin, thiotepa and cyclophosphamide (CTC). DNA from 40 tumors was tested for the presence of the BRCA1-profile by aCGH. Furthermore, we screened for the majority of BRCA1 and BRCA2 mutations that frequently occur in Dutch BRCA1 and BRCA2 families.&amp;#x2028; Results: Sixteen patients had a tumor with a BRCA1-profile and had a better response to CTC-treatment, defined by achievement of a complete remission (p=0.01) and longer PFS (p=0.001, figure 1), with a hazard ratio for progression of 0.30 (p=0.002).&amp;#x2028; &amp;#x2028; All 6 patients who remain in continuous complete remission (56+ to 150+ months) had a tumor with a BRCA1 profile. Two BRCA1 and 2 BRCA2 mutations were found in 4 patients of whom 3 had a BRCA1-profile and a long PFS (&amp;gt; 30months), linking HR deficiency (BRCA1 and BRCA2 mutations) in breast cancer patients to good outcome on platinum-based chemotherapy.&amp;#x2028; Discussion: Using an aCGH classifier initially constructed to identify BRCA1-mutated tumors we were able to identify a group of metastatic breast cancer patients treated with platinum-based chemotherapy with a high complete remission-rate and long progression free survival. Moreover, this group contained all patients who were apparently cured by intensive alkylating chemotherapy. Our aCGH assay may represent an effective test for BRCA-ness and could be important to select patients with sporadic tumors for therapy targeted at cells deficient in Homologous Recombination. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6050.
Shedding Light on Melanocyte Pathobiology <i>In Vivo</i>
Authors: M. Raza Zaidi, Edward C. De Fabo, Frances P. Noonan, Glenn Merlino
Journal: Cancer Research (2012)

Cutaneous malignant melanoma is rapidly increasing in the developed world and continues to be a challenge in the clinic. Although extensive epidemiologic evidence points to solar UV as the major risk factor for melanoma, there is a significant gap in our knowledge about how this most ubiquitous environmental carcinogen interacts with the largest organ of the mammalian body (skin) at the microenvironmental and molecular level. We review some recent advances that have started to close this gap.
Targeting Cancer Stem–like Cells as an Approach to Defeating Cellular Heterogeneity in Ewing Sarcoma
Authors: Sandrine Cornaz-Buros, Nicolo Riggi, Claudio DeVito, Alexandre Sarre, Igor Letovanec, Paolo Provero, Ivan Stamenkovic
Journal: Cancer Research (2014)

Plasticity in cancer stem-like cells (CSC) may provide a key basis for cancer heterogeneity and therapeutic response. In this study, we assessed the effect of combining a drug that abrogates CSC properties with standard-of-care therapy in a Ewing sarcoma family tumor (ESFT). Emergence of CSC in this setting has been shown to arise from a defect in TARBP2-dependent microRNA maturation, which can be corrected by exposure to the fluoroquinolone enoxacin. In the present work, primary ESFT from four patients containing CD133(+) CSC subpopulations ranging from 3% to 17% of total tumor cells were subjected to treatment with enoxacin, doxorubicin, or both drugs. Primary ESFT CSC and bulk tumor cells displayed divergent responses to standard-of-care chemotherapy and enoxacin. Doxorubicin, which targets the tumor bulk, displayed toxicity toward primary adherent ESFT cells in culture but not to CSC-enriched ESFT spheres. Conversely, enoxacin, which enhances miRNA maturation by stimulating TARBP2 function, induced apoptosis but only in ESFT spheres. In combination, the two drugs markedly depleted CSCs and strongly reduced primary ESFTs in xenograft assays. Our results identify a potentially attractive therapeutic strategy for ESFT that combines mechanism-based targeting of CSC using a low-toxicity antibiotic with a standard-of-care cytotoxic drug, offering immediate applications for clinical evaluation.
M &amp; B 693 in Gonorrhoea
Authors: R. C. L. Batchelor, R. Lees, M. Murrell, G. I. H. Braine
Journal: BMJ (1938)

AUIDICAL JOURNALwas the Kenya Group IV type Kw.D. (Type VIII of the American series).Case 2.-An elderly male European with lobar pneumonia; severe Type 11 infection.M.P.W. vaccine was given on the third day of illness.The temperature was 101.5°the same evening but dropped to 97.5°at 6 o'clock the next morning, the patient feeling better and being less cyanosed; the tem- perature rose to 99.6°the same evening.Vaccine was given again the following day, when the temperature was subnormal.Convalescence was regular from that date.The doctor in charge of the patient wrote, "One of the most successful cases of lobar pneumonia I ever had."Case 3.-A female European with lobar pneumonia; severe Type III infection.M.P.W. vaccine was given late in the illness.The only notes available are the doctor's report that it was a good case and the patient made a quick recovery, the crisis occurring forty hou-rs after the vaccine injection.Case 4.-A female European with lobar pneumonia; ex- tremely severe Type I infection.M.P.W. vaccine was given-2,00p millions.The patient was said by the doctor in charge to be moribund when the first injection of vaccine was made, and he regarded this as the last hope.The next morning her condition was reported satisfactory.A second injection was given forty-eight hours after the first, and the crisis occurred within the next twenty-four hours.The doctor said that the vaccine " worked a miracle for the patient."Case 5.-A male African with lobar pneumonia; severe infecting pneumococcus type " Kw.S."The mouse peritoneal exudate from which the vaccine was made included also a strain of Friedlander's bacillus, in numbers exceeded by the pneumococci, so that the vaccine necessarily contained both types of organism.M.P.W. vaccine was given; there was no toxic reaction.Crisis occurred the following day and con- valescence was easy.This native case is included here because it was the only one in which a mixed vaccine was used, and it is typical of the few satisfactory native cases that were collected.Case 6.-An elderly male European who had lobar pneu- monia, Type I infection, which proved fatal.He was given 0.08 mg. of M.P.W. vaccine.The only report received on this case was that the vaccine had " no effects."
Courage is treating patients with Ebola
Authors: M. McCartney
Journal: BMJ (2014)

doctor in Sierra Leone, knew the risks."I am afraid for my life, I must say, because I cherish my life," he said."Health workers are prone to the disease because we are the first port of call for somebody who is sickened by the disease.Even with the full protective clothing you put on, you are at risk." 1 His words came before he contracted Ebola virus and died on 29 July. 2 Three nurses he worked with had already died from the disease. 3And the World Health Organization has described this as the worst Ebola outbreak ever, with more than 660 deaths in Guinea, Sierra Leone, and Liberia. 4 This highly infective virus is likely to cause death, with no vaccination and little other than supportive treatment available.
Do drug offences matter?
Authors: A M Gordon
Journal: BMJ (1978)

Drug offences in addicts are often thought to indicate little more than continued dependency. In a four-year follow-up study of 60 men attending a drug clinic a history of repeated convictions for drug offences was found to be strongly related to patterns of delinquency. The following variables were associated with a history of repeated drug offences: a higher conviction rate for "non-drug" offences; younger age at first conviction; conviction preceding drug use; convictions for offences of sex and violence; longer prison sentences; and regular narcotic use and continued dependency at follow-up. Receiving a clinic prescription was not associated with a lower incidence of drug offences. Repeated drug offences identified a subgroup of drug users who were characterised by extensive sociopathic behaviour. Such offences should not be dismissed as an unavoidable, unimportant part of addiction.
The Acquired Immunodeficiency Syndrome in Gay Men
Authors: HAROLD W. JAFFE
Journal: Annals of Internal Medicine (1985)

The acquired immunodeficiency syndrome (AIDS) is a major health problem for gay men in the United States. About three fourths of all reported cases have occurred in this population, and the number is projected to double in the next year. In Manhattan and San Francisco, AIDS is now the leading cause of premature mortality in men aged 25 to 44 years who have never married. In a sample of a cohort of gay men enrolled in a San Francisco clinic, 2.7% of the men had the syndrome and 26% had related conditions in 1984. Antibody to human T-lymphotropic virus, type lll/lymphadenopathy-associated virus was found in sera from 67% of the men, including 58% of asymptomatic men. Behavioral factors associated with an increased risk of AIDS include large numbers of sexual partners, receptive anal intercourse, and "fisting." The adoption of safer lifestyles is currently the basis of attempts to control the syndrome in gay men.
Cellular Metabolic Lesion Patterns in Hyperlipemia.
Authors: Faber F. McMullen
Journal: Annals of Internal Medicine (1970)

Meeting Abstracts1 May 1970Cellular Metabolic Lesion Patterns in Hyperlipemia.Faber F. McMullen Jr., M.D., F.A.C.P., Mary M. Allen, Ph.D., Lawrence R. Rodgers, M.D., F.A.C.P., Keith H. Stonecipher, M.D.Faber F. McMullen Jr., M.D., F.A.C.P.Search for more papers by this author, Mary M. Allen, Ph.D.Search for more papers by this author, Lawrence R. Rodgers, M.D., F.A.C.P.Search for more papers by this author, Keith H. Stonecipher, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-72-5-790_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA distinctive pattern of rate-limiting enzyme activity for both anerobic and aerobic cycles of celluler metabolism in each class of hyperlipemia defined by Fredrickson as Normal, II, and IV was suspected and investigated.Fifteen patients under the age of 60 with arteriosclerotic coronary artery heart disease and myocardial infarction were removed from medication for 21 days and had skeletal muscle biopsy and erythrocytes collected. The patients were classified by measuring the plasma total lipid, triglyceride, cholesterol, and lipoprotein electrophoresis. The skeletal muscle and erythrocytes were analyzed by measuring the activity of the rate-limiting enzymes of glycolysis and accessory paths, Krebs... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Faber F. McMullenJr., M.D., F.A.C.P.; Mary M. Allen, Ph.D.; Lawrence R. Rodgers, M.D., F.A.C.P.; Keith H. Stonecipher, M.D.Affiliations: Houston, Tex. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1970Volume 72, Issue 5Page: 790-790KeywordsCholesterolCoronary artery heart diseaseEnzyme metabolismEnzymesHyperlipidemiaLesionsLipidsLipoproteinsMyocardial infarctionSkeletal muscles ePublished: 1 December 2008 Issue Published: 1 May 1970 PDF downloadLoading ...